Golden Biotechnology Balans Gezondheid
Financiële gezondheid criteriumcontroles 1/6
Golden Biotechnology has a total shareholder equity of NT$240.7M and total debt of NT$284.6M, which brings its debt-to-equity ratio to 118.2%. Its total assets and total liabilities are NT$578.0M and NT$337.2M respectively.
Belangrijke informatie
118.2%
Verhouding schuld/eigen vermogen
NT$284.65m
Schuld
| Rente dekkingsratio | n/a |
| Contant | NT$89.36m |
| Aandelen | NT$240.72m |
| Totaal verplichtingen | NT$337.23m |
| Totaal activa | NT$577.95m |
Recente financiële gezondheidsupdates
Geen updates
Analyse van de financiële positie
Kortlopende schulden: 4132's short term assets (NT$194.3M) do not cover its short term liabilities (NT$300.7M).
Langlopende schulden: 4132's short term assets (NT$194.3M) exceed its long term liabilities (NT$36.5M).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: 4132's net debt to equity ratio (81.1%) is considered high.
Schuld verminderen: 4132's debt to equity ratio has increased from 23.4% to 118.2% over the past 5 years.
Balans
Analyse van de cashflow
Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.
Stabiele cash runway: 4132 has less than a year of cash runway based on its current free cash flow.
Voorspelling contante baan: 4132 has less than a year of cash runway if free cash flow continues to grow at historical rates of 2.4% each year.